Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors-phase I trial: 2nd report

Haemophilia

Volumn 19, Issue 2, 2013, Pages 330-337

  Shirahata, A ^a   Fukutake, K ^b   Mimaya, J ^c   Takamatsu, J ^d   Shima, M ^e   Hanabusa, H ^f   Takedani, H ^g   Takashima, Y ^c   Matsushita, T ^h   Tawa, A ⁱ   Higasa, S ^j   Takata, N ^k   Sakai, M ^a   Kawakami, K ^l   Ohashi, Y ^g   Saito, H ^m  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

^d NAGOYA UNIVERSITY HOSPITAL   (Japan)

^e NARA MEDICAL UNIVERSITY   (Japan)

^f Ogikubo Hospital   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

^h NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ OSAKA NATIONAL HOSPITAL   (Japan)

^j HYOGO COLLEGE OF MEDICINE   (Japan)

^k HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^l Kagoshima City Hospital   (Japan)

^m NAGOYA CENTRAL HOSPITAL   (Japan)

more..

Author keywords

Bypassing agent; Clot waveform analysis; Factor VIIa; Factor X; Haemophiliacs with inhibitors; Thrombin generation test

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; MC710; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CLOT WAVEFORM ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MALE; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SAMPLING; THROMBIN TIME; WAVEFORM;

ADOLESCENT; ADULT; BLOOD COAGULATION; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION TESTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FACTOR VIIA; FACTOR X; HEMOPHILIA A; HEMOPHILIA B; HUMANS; JAPAN; MALE; THROMBIN; YOUNG ADULT;

EID: 84874092003     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12024     Document Type: Article

References (16)

1. Gringeri A, Fischer K, Karafoulidou A, Klamroth R, López-Fernández MF, Mancuso E. European Haemophilia Treatment Standardisation Board (EHTSB). Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with hemophilia and inhibitors. Haemophilia 2011; 17: 630-5.
2. Nakatomi Y, Nakashima T, Gokudan S et al. Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa/FX mixture as an alternative bypassing agent. Thromb Res 2010; 125: 457-63.
3. Tomokiyo K, Nakatomi Y, Araki T et al. A novel therapeutic approach combining human plasma-derived factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with factor VIIa alone. Vox Sang 2003; 85: 290-9.
4. Shirahata A, Fukutake K, Mimaya J et al. Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors - Phase I trial Haemophilia 2012; 18: 94-101.
5. Shima M, Matsumoto T, Fukuda K et al. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost 2002; 87: 436-41.
6. Hemker HC, Giesen PL, Ramjee M, Wagenvoord R, Beguin S. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000; 83: 589-91.
7. Downey C, Kazmi R, Toh CH. Early identification and prognostic implications in disseminated intravascular coagulation through transmittance waveform analysis. Thromb Haemost 1998; 80: 65-9.
8. Matsumoto T, Wada H, Nishioka Y et al. Frequency of abnormal biphasic aPTT clot waveforms in patients with underlying disorders associated with disseminated intravascular coagulation. Clin Appl Thromb Hemost 2006; 12: 185-92.
9. Shima M. Understanding the hemostatic effects of recombinant factor VIIa by clot waveform analysis. Semin Hematol 2004; 41(Suppl. 1): 125-31.
10. Castoldi E, Rosing J. Thrombin generation tests. Thromb Res 2011; 127(Suppl. 3): S21-5.
11. Brummel-Ziedins KE, Vossen CY, Butenas S, Mann KG, Rosendaal FR. Thrombin generation profiles in deep venous thrombosis. J Thromb Haemost 2005; 3: 2497-505.
12. Hoffman M, Monroe DM. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol 2001; 38(Suppl. 12): 6-9.
13. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-7.
14. Monroe DM, Hoffman M, Oliver JA, Roberts HR. A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul Fibrinolysis 1998; 9(Suppl. 1): S15-20.
15. Chen SW, Pellequer JL, Schved JF, Giansily-Blaizot M. Model of a ternary complex between activated factor VII, tissue factor and factor IX. Thromb Haemost 2002; 88: 74-82.
16. Ndonwi M, Broze G Jr, Bajaj SP. The first epidermal growth factor-like domains of factor Xa and factor IXa are important for the activation of the factor VII-tissue factor complex. J Thromb Haemost 2005; 3: 112-8.